Medigen Biotechnology Corp.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Medigen Biotechnology Corp.
The company, which has treatments in the clinic for CLN2 Batten disease and APOE4-associated Alzheimer’s disease, is developing AAV-mediated gene therapies designed for safer outcomes.
In a series on articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are six new anti-infectives expected to reach the market for the first time next year, all with an above average likelihood of approval.
Clinical-stage biopharma Starton Therapeutics is developing continuous delivery systems and transdermal technologies to improve the safety and efficacy of existing cancer medications, and eschewing VC firms in favor of retail investors. Chair and CEO Pedro Lichtinger recently appeared on Unicorn Hunters, an online reality TV show, to pitch the company to celebrity judges, and the public at large.
Device company Medicrea, which was recently acquired by Medtronic, is paying $2m to resolve allegations the company violated both the False Claims Act and the Open Payments Program.
- Other Names / Subsidiaries
- Medigen Vaccine Biologics Co.
- Medigen Vaccinology Corp.